Orchestra Biomed Holdings, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
David Pacitti, a Director of Orchestra BioMed Holdings, Inc., reported a transaction in 3,761 shares of common stock on August 12, 2026.
NASDAQ
John Prosper Mack, a Director of Orchestra BioMed Holdings, Inc., reported a transaction in 4,885 shares of common stock on August 12, 2026.
NASDAQ
Chris Cleary, a Director of Orchestra BioMed Holdings, Inc., reported a transaction in 4,238 shares of common stock on August 12, 2026.
NASDAQ
Darren Sherman, See Remarks and a Director of Orchestra BioMed Holdings, Inc., sold 15,000 shares of common stock on August 3, 2026 for $4.09 per share.
NASDAQ
Orchestra BioMed Holdings, Inc. reports a Form 4 filing detailing stock transactions by Director Eric S. Fain, including RSU awards and share withholding for tax obligations.
NASDAQ
David Pacitti, a Director at Orchestra BioMed Holdings, Inc., acquired restricted stock units and stock options on June 23, 2026, as part of his compensation.
NASDAQ
Orchestra BioMed Holdings, Inc. director Chris Cleary acquired stock options and had shares withheld for tax obligations related to RSU vesting.
NASDAQ
Orchestra BioMed Holdings, Inc. reports that Director Pamela Ann Connealy was granted restricted stock units and stock options on June 23, 2026.
NASDAQ
Orchestra BioMed Holdings, Inc. director Aryeh Jason was granted stock options for 42,553 shares.
NASDAQ
Orchestra BioMed Holdings, Inc. Director John Prosper Mack reported transactions involving restricted stock units and common stock.
NASDAQ
CFO Andrew Taylor reported the withholding of 36,352 shares of Orchestra BioMed common stock to satisfy tax obligations related to RSU vesting.
NASDAQ
David P. Hochman, Director and Officer of Orchestra BioMed Holdings, Inc., acquired 5,000 shares of common stock on June 1, 2026, at a weighted average price of $3.83 per share.
NASDAQ
Darren Sherman, Director and Officer of Orchestra BioMed Holdings, Inc., reported the sale of 15,000 shares of common stock on June 1, 2026, executed under a Rule 10b5-1 trading plan.
NASDAQ
CFO Andrew Taylor reported the withholding of 3,076 shares of Orchestra BioMed common stock to satisfy tax obligations related to RSU vesting.
NASDAQ
Darren Sherman, President and COO of Orchestra BioMed, reported a routine tax-related share withholding transaction.
NASDAQ
Orchestra BioMed Holdings, Inc. Director Aryeh Jason reported the purchase of 665 shares of common stock for $3.75 per share.
NASDAQ
Orchestra BioMed Holdings, Inc. Director Aryeh Jason reported a purchase of 8,971 shares of common stock.
NASDAQ
David P. Hochman, Director and Officer of Orchestra BioMed Holdings, Inc., acquired 5,000 shares of common stock.
NASDAQ
Orchestra BioMed Holdings, Inc. reports a Form 4 filing detailing a stock acquisition by Director Eric S. Fain.
NASDAQ
RTW Investments, LP, through its affiliated funds, exercised pre-funded warrants for Orchestra BioMed Holdings, Inc. common stock, resulting in a net increase in beneficial ownership.
NASDAQ
Orchestra BioMed Holdings, Inc. Director and COO Darren Sherman reported a disposition of 33,317 shares for tax withholding related to RSU vesting.
NASDAQ
Orchestra BioMed's Principal Accounting Officer, Joshua Aiello, reported a disposition of 241 shares for tax withholding related to RSU vesting.
NASDAQ
Orchestra BioMed Holdings, Inc. CEO David P. Hochman reported a disposition of 32,438 shares for tax withholding related to RSU vesting.
NASDAQ
Orchestra BioMed Holdings, Inc. CEO and Chairperson David P. Hochman purchased 10,000 shares of common stock, signaling strong insider confidence.
NASDAQ
Orchestra BioMed's Principal Accounting Officer, Joshua Aiello, was granted 70,000 stock options with a $3.82 exercise price, vesting over several years.
NASDAQ
Orchestra BioMed Holdings, Inc. awarded President and COO Darren Sherman 397,000 restricted stock units, vesting over three years.
NASDAQ
Orchestra BioMed Holdings, Inc. Chief Financial Officer Andrew Taylor was granted 181,000 restricted stock units, vesting over three years.
NASDAQ
Orchestra BioMed Holdings, Inc.'s CEO and Chairperson, David P. Hochman, was granted 504,000 restricted stock units, vesting over three years.
NASDAQ
Orchestra BioMed Holdings Director Chris Cleary reported a tax-related withholding of 676 shares of common stock.
NASDAQ
Orchestra BioMed Holdings, Inc. disclosed that its President and Chief Operating Officer, Darren Sherman, was granted 34,974 performance stock options.